The US Centers for Medicare and Medicaid Services (CMS) has rejected broader coverage of new amyloid-targeting Alzheimer’s disease treatments, a decision branded “pernicio
The FDA's interactions with Biogen in the build-up to last year's controversial approval of Alzheimer's disease therapy Aduhelm have been described as "inappropriate" and "atypical" in a co
A bipartisan bill has been introduced in the US Congress that will try to block Centers for Medicare and Medicaid Services (CMS) restrictions on Biogen's Alzheimer's therapy Aduhelm being e
Biogen and Eisai have resurrected hopes that amyloid-targeting drugs could have a benefit in Alzheimer's disease with a claim that their new drug lecanemab showed a "highly statistically si
The FDA has started an accelerated review of Eisai and Biogen's a new amyloid-targeting antibody lecanemab for Alzheimer's disease, with a 6 January deadline that keep them ahead of closest
Inato has raised $20 million in early-stage financing to support the continued development of its clinical trial marketplace, which connects sponsors with its network of t